KPTI News and Press, Karyopharm Therapeutics Inc. From 05/04/23

2023-05-04 12:56:38 ET Shares of Karyopharm Therapeutics ( NASDAQ: KPTI ) fell ~24% on Thursday to hit the lowest level since December after the oncology-focused biotech trimmed its full-year outlook despite beating Wall Street forecasts with its Q1 2023 financials. Due to a...

2023-05-04 09:27:10 ET Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q1 GAAP EPS of -$0.30 beats by $0.08 . Revenue of $38.7M (-18.8% Y/Y) beats by $1.49M . Based on its current operating plans, Karyopharm is updating its guidance for full year 2023...

Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved First Quarter 2023 Total Revenues of $38.7 Million , including XPOVIO® (selinexor) Net Product Revenue of $28.3 Million , Adversely Imp...

Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS PR Newswire – Relapsed/Refractory MDS Patients Achieved Median O...

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023 PR Newswire – At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Popul...

2023-04-14 17:30:31 ET Gainers: Elevation Oncology ( ELEV ) +23% . Kezar Life Sciences ( KZR ) +16% . Vimeo ( VMEO ) +5% . Karyopharm Therapeutics ( KPTI ) +4% . LivaNova  ( LIVN ) +3% . Losers: Silence Therapeutics&...

Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Naïve Myelofibrosis at AACR and to Host Investor Webcast on April 18th PR Newswire – Updated Safety and Efficacy Data Will be Presented in a Poster Session at AACR 2023 from A...

2023-03-20 04:43:40 ET Summary Shares are down 50% over the past year as fierce competition in the multiple myeloma space negatively impacts Xpovio's growth prospects. However, there is significant optionality via expansion opportunities into new indications, starting with relapse...

2023-03-14 00:09:42 ET Summary Karyopharm Therapeutics develops drugs for cancer and other diseases. Its main drug, Xpovio (selinexor), treats multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). Despite gaining approval for the treatment of MM and DLBCL, Karyopharm is...

2023-03-10 13:20:19 ET Whether you’re trading penny stocks or higher-priced shares of larger companies, there’s no denying that new and more frequent trends have come to light. Thanks to the huge move in “Ape stocks” during the pandemic, traders are becoming ...